A ldosterone (aldo) plays a key role in the control of sodium and potassium balance in the distal tubule of the kidney, thus regulating water body content and blood pressure (BP). Aldo acts through the mineralocorticoid receptor (MR), which is a ligandactivated transcription factor. Alteration of the aldo and MR signaling cascade leads to salt-wasting syndromes or hypertension.
and stroke. 13 In most clinical situations, the respective contributions of renin, angiotensin II (Ang II), aldo, and MR are difficult to assess because of their simultaneous involvement and interaction. 14, 15 Indeed, experimental models have illustrated a crosstalk between Ang II and aldo signaling in cardiac remodeling and progression of kidney damage. [15] [16] [17] [18] Type 1 pseudohypoaldosteronism (PHA1) is a rare disease of mineralocorticoid resistance. [19] [20] [21] Despite extremely high plasma renin and aldo levels, patients present with neonatal salt wasting and failure to thrive, hyponatremia, hyperkalemia, and metabolic acidosis. Generalized and renal forms of the disease differ at both the clinical and genetic levels. 21 Renal PHA1 is an autosomal-dominant form of mineralocorticoid resistance phenotypically restricted to the kidney in which neonatal salt wasting typically improves with age. Inactivating mutations in the NR3C2 gene, which codes for the MR, are responsible for renal PHA1 with >100 different mutations identified. 20, [22] [23] [24] Only a few reports have described the clinical and biological status of adult carriers (Cs) with MR mutations. 25, 26 Consequently, adult patients with renal PHA1 represent a unique population with a lifelong increase in plasma aldo concentration, normal or low BP, and MR haploinsufficiency. This condition not only allows dissociation of the respective effects of aldo, and BP on the CV system, but also addresses the pathophysiological relevance of the rapid and non-genomic actions of aldo, 17 and the involvement/ requirement of MR for these effects.
We aimed to describe the natural history of PHA1 in a casecontrol study comparing adult Cs and noncarriers (NCs) of MR mutations recruited through the PHA1.NET network. In particular, we assessed in detail cardiac and vascular status in the unique clinical setting of renal PHA1 (ie, normal or low BP and chronic high plasma aldo). Given that adult Cs were a young population, mainly parents of index cases, we focused on the preclinical CV alterations.
Methods

Study Design
PHACARV (Cardiovascular Evaluation of Adult PHA 1, Assistance Publique-Hôpitaux de Paris, PHRC P070139) is a single center, casecontrol study comparing C and NC subjects paired for sex and age (±5 years).
Recruitment and Eligibility
Subjects were recruited from 2008 to 2011 through the PHA1.NET cohort of PHA1 pedigrees (Principal Investigator MC Zennaro). Pedigrees with NR3C2 mutations (renal PHA1) were eligible; adults, aged >18 years, were contacted through the pediatrician in charge of the index case and gave written informed consent for genetic and clinical investigations. The study was approved by the institution review board (Comité de Protection des Personnes Ile de France I, authorization number 0811705). The NC family members served as controls. Subjects were non-consanguineous and were classified as NCs by NR3C2 sequencing showing absence of MR mutations. NCs were mother or father of the index case and occasionally siblings, grandmother, or grandfather. No pairing was possible within individual pedigrees, thus C and NC pairs were genetically unrelated individuals.
NCs with previously known CV disease were excluded (3 for hypertension). Participation of pregnant women was planned ≥6 months after delivery. Personal and family history was assessed through questionnaires. Personal health booklets were obtained at visit, and body weight of the first month of life was analyzed. Clinical PHA1 was considered likely when birth weight was not caught up within the first 3 weeks of life.
Cardiac and Vascular Ultrasound Studies
Comprehensive echocardiography and vascular carotid imaging were performed by the same investigator (Vivid 7, General Electric, Horten, Norway). Data were analyzed offline by an operator blind for the genotype of the subject (EchoPACTM, General Electric Ultrasound). Aortic pulse wave velocity was measured by the carotid-to-femoral method (see Methods in the online-only Data Supplement).
Cardiac MRI
Cardiac MRI was performed (Twinspeed 1.5 Tesla system, General Electric, Milwaukee, WI) with intravenous gadolinium chelate injection (Dotarem, meglumine gadoterate, Guerbet, Aulnay-sous-bois, France) for delayed-enhancement study. Cardiac MRI interpretations were made by 2 experienced readers, blind of clinical data (see Methods in the online-only Data Supplement).
Extracellular Water Measurement
Extracellular water (ECW) was measured by multifrequency spectroscopic bioimpedance (Analycor XF: Spengler, Cachan, France; see Methods in the online-only Data Supplement). The difference between the measured ECW to the upper or lower limit of the reference range was computed as ECW deviation.
BP and Autonomic Nervous System Evaluation
A 24-hour BP recording was performed at 15-minute intervals during day time and 30-minute intervals during the night (mean of 63 measures over an average of 22.7 hours) with separate analysis of supine and upright data (Diasys integra II, Diasysoft 4.6.3, Novacor, France). Autonomic nervous system (ANS) evaluation was performed from the 15-minute simultaneous BP and ECG recordings via a finger plethysmograph and surface ECG (AD-Instruments). Baroreflex sensitivity was also measured by cross-spectral analysis (see Methods in the online-only Data Supplement).
Statistical Analysis
Given the importance of age and sex for CV status, Cs and NCs were matched for age (±5 years) and sex. Matching was achieved between subjects from different non-consanguineous pedigrees because matching within individual pedigrees was not possible. Data are shown as median and range for continuous variables and number and percentage for categorical variables. Clinical and biochemical characteristics were compared between Cs and NCs with nonparametric paired tests (Cochran-Mantel-Haenszel or Wilcoxon test) and Wilcoxon or Fisher exact tests for familial history. Family history and cause of death between C and NC relatives were also compared taking into account within family correlation using univariate generalized linear-mixed effects models with family as random effect (using SAS [Statistical Analysis System 9.3, Institute Inc., Cary, NC] procedure GLIMMIX [generalized linear mixed model for SAS]). Using this analysis, no P value was obtained for those variables that were present only in cases belonging to one or the other group (Cs or NCs), but not in both. In the study design, 1 group of variables was classified as the primary criterion (21 variables for CV evaluation; Table 1 ) and 4 groups as the secondary criteria (15 variables for Na balance and RAAS, Table 2 ; 3 variables for Na intake and body composition and 12 variables for BP, Table 3 ; and 15 variables for ANS; Table IV in the online-only Data Supplement). For these criteria, to correct for multiple testing, the Benjamini-Hochberg correction was used, and critical values are indicated in tables. If a P value was less than the corresponding critical value, the test was significant.
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Results
Population
Eighty-three adult subjects were recruited from 41 independent PHA1 pedigrees. Nine pedigrees participated with NCs only, 13 with only Cs, 19 with both Cs and NCs, and 13 with >1 Cs or NCs (4 with 2 Cs, 9 with 2 NCs, 1 with 3 NCs, and 1 with 3 Cs). Biochemical and genetic characteristics of the index cases of each family are detailed in Results and Figure I in the online-only Data Supplement). Three NCs and 1 C were excluded because of impossible pairing. Clinical and biochemical characteristics are described in Table II in the online-only Data Supplement.
Cardiovascular Phenotype of MR Mutation Carriers
Our primary criterion was a detailed CV evaluation based on 21 variables investigating mild morphological or functional alterations (Table 1) . No cardiac remodeling was detected, as left ventricular (LV) and left atrium volumes, LV mass, and relative wall thickness were not significantly different between Cs and NCs, indicating no LV hypertrophy or dilatation. No LV fibrosis was found at cardiac MRI with no delayed enhancement after gadolinium injection. Systolic LV function was not different in Cs and NCs, as assessed by ejection fraction, tissue Doppler, and global longitudinal LV strain. Remarkably, LV diastolic function was significantly improved in Cs, compared with NCs, with greater e′ and lower E/e′ ratio, and a trend toward smaller left atrium size (Figure 1) . ECG was normal except in a few subjects: PR interval >200 ms in 2 Cs and 2 NCs or <120 ms in 1 C and 1 NC, QRS interval >100 ms in 3 Cs and 6 NCs, QTc interval >450 ms in 3 Cs and 1 NC.
No vascular remodeling was found in Cs at the common carotid artery and ascending aorta, and pulse wave velocity was not different between Cs and NCs.
Electrolyte Homeostasis and RAAS in Adult Carriers of MR Mutations
One of the secondary criteria of the study addressed the consequences of MR mutations on plasma electrolyte concentrations and the RAAS (Table 2 ). In C subjects, a significant increase in plasma protein levels indicated moderate hemoconcentration, and a significant decrease in plasma Na concentration suggested chronic sodium depletion. Twenty-four-hour urinary Na excretion showed a trend toward an increase, which 
Body Composition, BP, and ANS in Adult Carriers of MR Mutations
The consequences of MR mutation on body composition, BP, and ANS were assessed in 3 secondary criteria described in Table 3 and Table IV in the online-only Data Supplement. In adult Cs, sodium appetite, which was measured by the addition of Na salt on a sodium-free meal, was significantly increased ( Figure 3A ). ECW was not significantly different between Cs and NCs ( Figure 3B ). Twenty-four-hour ambulatory BP recording (obtained for 37 Cs and 38 NCs) showed no significant difference in mean, systolic or diastolic BP ( Figure 3C ), and heart rate. Upright BP and heart rate, and BP and heart rate variation from supine to upright position were not different between Cs and NCs, showing no significant upright hypotension. As a normal BP could result from activation of the ANS, its activity was evaluated by temporal and spectral analysis of heart rate and BP variability, and by measuring the baroreflex (Table IV in the online-only Data Supplement). No significant difference in ANS activity was found between C and NC subjects.
Personal and Family History
Analysis of body weight curves during the first month of life suggested clinical manifestations related to PHA1 in 51% of Cs and in 0% of NCs (P<0.001; Tables 4). C subjects also reported more often clinical symptoms of hypotension (P=0.004). CV disease before visit was identified only in a few subjects: coronary heart disease in 2 Cs, stroke in 1 NC, and cardiac murmur associated with low-grade (1 or 2) valvular disease in 3 Cs and 4 NCs. CV risk factors were not significantly different between Cs and NCs ( Table I in the online-only Data Supplement). Personal history disclosed a higher frequency of miscarriage in female Cs (P=0.004), but no increase in prematurity, and an increase in history of depression in Cs, compared with NCs (P=0.046). Past medical history and cause and age of death in family members were only analyzed in families in which an MR mutation was identified in ≥1 ancestor of the index case. This identified, on the one hand, the family ancestors' potentially carriers of the mutation (C relatives) and, on the other hand, the family ancestors' noncarriers of the mutation (NC relatives). Thirty-four family branches were analyzed (19 from female Cs and 15 from male Cs) and compared with 32 NC family branches, given that in 1 family both parents were carriers of different MR mutations. 28 Only 7 families had genetically proven PHA1 in relatives other than the father or mother (aunt, uncle, or grandparents). Medical records of dehydration in infancy or failure to thrive were significantly more frequent in C families (Tables 5). Hypotension was more frequently reported and hypertension less frequently diagnosed in the C branch of the families than in the NC branch. CV diseases, metabolic disorders, and psychiatric disease were reported with the same frequency in C and NC families. C branches obtained a significantly greater number of records when the mother was Cs (P=0.03), as compared with NCs. This may have led to an overestimation of the number of events in C families, thus concealing CV protection.
Death occurred at a younger age in C relatives, with no difference when considering age of death after 1 year of age ( Table 6 ). As a consequence of the severity of the disease in newborns, the causes of death before year 1 was analyzed separately. Besides a greater number of reported miscarriages in C families, death before 1 year of age associated with a saltwasting syndrome was rare ( 
Discussion
We report that adult subjects carrying MR mutations have lifelong activation of the RAAS and moderate increase in sodium appetite, which allow maintaining a normal sodium balance with normal BP and ECW and no sign of ANS activation. Despite chronic activation of the RAAS, these subjects display normal cardiac and vascular function and outcome.
Aldo and MR have been shown to be important cardiovascular risk factors independent of BP. Aldo was shown to be responsible for cardiac remodeling and fibrosis in patients with primary aldosteronism. [8] [9] [10] Increased MR activation is involved in end-organ damage, including vascular remodeling with intimal thickening, adventitial fibrosis, perivascular inflammation with macrophage infiltration and impaired vascular reactivity, and progression of chronic kidney disease. 3, 29, 30 PHA1 is a unique situation in which MR function is rate limiting in the presence of high plasma aldo, resulting in normal or low MR-mediated signaling. In contrast, renin and Ang II are expected to exert full effects in this setting. Adult PHA1 patients, carriers of loss-of-function MR mutations, therefore, enabled the evaluation of the respective importance of renin, Ang 2, aldo, and MR-dependent effects on the CV system in the presence of a moderate increase in sodium intake. In our study, despite a careful search for mild or preclinical alterations using cardiac and vascular imaging and functional assessment, no significant difference was detected between Cs and NCs, with no sign of cardiac fibrosis or remodeling, and no vascular wall thickening, remodeling, or stiffness. PHA1 patients show plasma aldo concentrations (0.9 nmol/L) in a range very similar to that reported in patients with primary aldosteronism (0.55-1 nmol/L) and accelerated CVD, [8] [9] [10] 31 including young patients with familial hyperaldosteronism (with a median age of 19 years) who have no hypertension but detectable LV hypertrophy and diastolic dysfunction (decreased e′). 8 This indicates that, despite the young age of the patients, our study had the power to reveal cardiac alterations, if present, in PHA1. Our results demonstrate that increased aldo levels and a moderate chronic activation of renin (and most probably Ang II) are not sufficient to induce CV alterations in PHA1 patients over years, supporting a requirement for full MR activity for RAASdependent deleterious CV effects. Indeed, interactions among aldo, MR, and Ang II signaling were shown in heart, kidney, and vessels. 16, 32 This central role of MR signaling might thus explain the benefits of MR blockade in clinical situations or experimental models with chronically high MR stimulation, such as acute phase of myocardial infarction, heart failure, and chronic kidney disease. 5, 6, 15, 33 In addition to MR activation, rapid responses to aldo have also been described involving GPR30 as a membrane receptor. 18, 34 Our results suggest that GPR30-mediated signaling linked to aldo is either not involved or minor in the CV effects of aldo, or requires normal MR activity and possibly interactions with other pathways such as Ang II. 16, 32 Our results show better diastolic parameters (e′ and E/e′) in PHA1 patients. Echographic measurements of LV diastolic function are dependent on both preload and afterload, but change in loading conditions is unlikely to explain this finding, as BP and ECW were not significantly different between Cs and NCs. PHA1 patients have reduced but not absent MR signaling, because they carry heterozygous mutation. Given that impaired diastolic function is a sign of early cardiac involvement in CVD, improved diastolic function might be the only sign of better CV status associated with MR mutation. In young patients with familial hyperaldosteronism, altered diastolic function with LV hypertrophy 8 suggests that aldosterone might target diastolic function, in addition to cardiac fibrosis and remodeling. 31 This might contribute to the beneficial effects of aldosterone blockade in patients with mild heart failure 7, 35 and in patients with impaired diastolic function and preserved systolic function (aldo-diastolic heart failure trial released at the European Society of Cardiology Meeting 2012). 36 Given that higher aldosterone levels in PHA1 may reflect a more severe impairment of MR function, the finding of a better LV systolic function in the upper quartile of aldo in Cs further supports the central role of MR signaling in mediating deleterious CV effects of aldo. The mechanisms involved in the effects on diastolic function were not addressed in our study but could be related to changes in L-type calcium channel activity, as reported in cellular models 37 and in mice overexpressing MR in cardiomyocytes, 16, 38 or to MR effects on cardiac endothelial function. 39 Homozygous MR knockout mice recapitulate the renal phenotype of a severe renal PHA1, which can be rescued by Na supplementation. 40 Heterozygous mice have a mild renal phenotype and moderate RAAS activation, but their CV status has not been investigated in detail. Similarly, the CV status of mice with MR inactivation specifically in the distal nephron, which develop a salt-wasting syndrome and strong RAAS activation, is unknown. 41 Other diseases that affect sodium balance may provide further insight into the cardiovascular effects of aldo and MR. Bartter and Gitelman syndromes are 2 rare distal tubular disorders with chronic sodium and potassium wasting. In Gitelman syndrome, renin and Ang II are increased, but aldo may be normal to low because of aldo suppression by marked hypokalemia. Patients with Gitelman syndrome show cardiac arrhythmias but no structural CV alteration 42 or increase in CV risk. 43 Conversely, patients with apparent mineralocorticoid excess, in which impaired activity of 11-β-hydroxysteroid dehydrogenase 2 allows glucocorticoids to activate MR despite low plasma aldo, have hypertension and early vascular complications. 44 Finally, the chronic use of MR antagonists for primary aldosteronism, heart failure, 6, 7 or myocardial infarction 5 strongly supports involvement of MR activation in aldodependent CV events, with a clear benefit of MR antagonists on top of optimal treatment, including angiotensin-converting enzyme or angiotensin II receptor type 1 inhibition.
Our study involved the largest cohort of adult subjects carrying MR mutations reported so far. As a consequence of the low frequency of the disease, reports on a small number of families could only suggest the complete remission of the salt-wasting syndrome. 25, 26 All mutations in our families are deleterious, as demonstrated experimentally or predicted by bioinformatics analysis. 25, 28, 45 Our study clearly demonstrates that in adult patients with PHA1, sodium balance is achieved through permanent and constant stimulation of the RAAS and modest increase in salt appetite without the need for chronic activation of the ANS or hypothalamo-pituitary-adrenal axis. In this study, PHA1 subjects were not evaluated in challenging conditions, such as sodium depletion, which could disclose limitations of adaptive responses, as suggested by C reporting episodes of dehydration. Interestingly, 50% of Cs had a birth history suggestive of PHA1 and recurrent episodes of dehydration in childhood. However, PHA1 was not diagnosed in the family until birth of a child with severe dehydration. In contrast to a previous report, 25 the family history did not disclose an increase in newborn mortality. This may be because of the standards of care that avoid severe dehydration in infants, even if the salt-wasting syndrome remains undiagnosed. The estimated prevalence of renal PHA1 is 1 per 80 000 births, but the true frequency of MR mutations in the general population might be underestimated. The description in 1 of our families of a newborn with severe recessive renal PHA1 caused by 2 distinct heterozygous NR3C2 mutations that were transmitted independently by the parents 28 suggests that MR variants might be more frequent than expected in the general population and may contribute to a significant fraction of the genetic variation of BP.
The increased frequency of miscarriage was not expected. It was observed only in female Cs, suggesting that pregnancy was involved rather than the fetal status for the disease. Human trophoblast and endometrium were shown to be a possible target tissue for aldo, with the expression of both MR and 11HSD2. 46, 47 Regulation of the epithelial sodium channel by aldo in trophoblasts, 48 promotion of placenta growth by aldo, 49 and involvement of epithelial sodium channel in embryo implantation 50 could be instrumental in the increased rate of miscarriage in our patients. Altered reproductive function might be a significant event encountered by adult PHA1 patients.
In contrast, causes of death in PHA1 families were not otherwise different from those in the French population, as reported for the past 14 years (≈30% from tumor and 30% from CV diseases; www.insee.fr). This finding indirectly argues for the absence of significant deleterious effects of RAAS activation in the absence of increased MR activity.
Limitations
A lower incidence of CV disease could have been expected in patients with PHA1 because of reduced MR activation. However, patients with renal PHA1 are heterozygous carriers of MR mutations. In this setting the protective effect of low MR activation on the CV system may be visible only in older patients, which could be addressed in a follow-up study of this population. However, in a younger population of patients with familial hyperaldosteronism (age, 19 years), a similar increase in plasma aldo but normal MR activity was associated with CV alterations, 8 suggesting that our study had the power to identify significant alterations in patients with PHA1 if present.
Conclusions
Despite a life-long increase in plasma aldo and renin levels, no adverse cardiovascular outcome occurred in PHA1, but rather an improved diastolic LV function. This finding suggests that the CV consequences of aldo excess require full MR signaling.
